Compare FOFO & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | MRKR |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 19.5M |
| IPO Year | 2025 | 2010 |
| Metric | FOFO | MRKR |
|---|---|---|
| Price | $2.01 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.87 |
| AVG Volume (30 Days) | ★ 194.4K | 162.3K |
| Earning Date | 12-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $19.61 |
| Revenue Next Year | N/A | $375.85 |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.70 | $0.84 |
| 52 Week High | $14.93 | $2.46 |
| Indicator | FOFO | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 43.06 |
| Support Level | $1.76 | $0.88 |
| Resistance Level | $2.68 | $1.34 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 28.57 | 26.97 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their business and investment objectives. Its business consists of two main business lines: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting and Regulatory compliance and governance consulting, and the asset management services, including fund subscription and fund management services.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).